Show notes
ASH 2025 Highlights:MajesTEC-3: Teclistamab + Daratumumab in relapse refractory Multiple MyelomaParadigm: HMA + Ven vs. 7+3 or CPX-351Denosumab safety & dosing in Multiply Myeloma and renal dysfunctionTrilaciclib and CDK 4/6 inhibition as protection against TP53-mutated clonal hematopoiesis?

